Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea
Authors:
Open Access
- 1 July 2024
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 39 (4) , 640-649
Abstract
Background/Aims: This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.Methods: This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.Results: Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51–358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32–366 d), which was significantly earlier than the median of 184 days (IQR 68–356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75–213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.Conclusions: This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.Keywords
This publication has 30 references indexed in Scilit:
- Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosisERJ Open Research, 2023
- Tuberculosis in older adults: challenges and best practices in the Western Pacific RegionThe Lancet Regional Health - Western Pacific, 2023
- A 24-Week, All-Oral Regimen for Rifampin-Resistant TuberculosisNew England Journal of Medicine, 2022
- Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or DelamanidClinical Infectious Diseases, 2021
- Trends and risk factors for death and excess all-cause mortality among notified tuberculosis patients in the UK: an analysis of surveillance dataERJ Open Research, 2019
- Trends in incidence and mortality of tuberculosis in Japan: a population-based study, 1997–2016Epidemiology and Infection, 2018
- Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyThe Lancet Respiratory Medicine, 2018
- Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysisScientific Reports, 2018
- Tuberculosis, social determinants and co-morbidities (including HIV)Pulmonology, 2018
- Tuberculosis among older adults – time to take noticeInternational Journal of Infectious Diseases, 2015